A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Degarelix (Primary) ; Degarelix (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms BLADE
- 16 Aug 2022 Results of an analysis explored the predictive role of body composition on treatment induced bone loss published in the Journal of Clinical Endocrinology and Metabolism
- 08 Nov 2020 Status changed from recruiting to completed.
- 30 Jun 2017 New trial record